Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia
- PMID: 38473775
- PMCID: PMC10932140
- DOI: 10.3390/ijms25052527
Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia
Abstract
This comprehensive review delves into the multifaceted roles of mesenchymal stem cells (MSCs) in leukemia, focusing on their interactions within the bone marrow microenvironment and their impact on leukemia pathogenesis, progression, and treatment resistance. MSCs, characterized by their ability to differentiate into various cell types and modulate the immune system, are integral to the BM niche, influencing hematopoietic stem cell maintenance and functionality. This review extensively explores the intricate relationship between MSCs and leukemic cells in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. This review also addresses the potential clinical applications of MSCs in leukemia treatment. MSCs' role in hematopoietic stem cell transplantation, their antitumor effects, and strategies to disrupt chemo-resistance are discussed. Despite their therapeutic potential, the dual nature of MSCs in promoting and inhibiting tumor growth poses significant challenges. Further research is needed to understand MSCs' biological mechanisms in hematologic malignancies and develop targeted therapeutic strategies. This in-depth exploration of MSCs in leukemia provides crucial insights for advancing treatment modalities and improving patient outcomes in hematologic malignancies.
Keywords: bone marrow microenvironment; clinical applications; hematopoietic stem cells; leukemia; mesenchymal stem cells.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Alteration of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes.J Cell Physiol. 2019 Apr;234(4):3697-3710. doi: 10.1002/jcp.27142. Epub 2018 Oct 14. J Cell Physiol. 2019. PMID: 30317554
-
Mesenchymal stromal cells derived from the bone marrow of acute lymphoblastic leukemia patients show altered BMP4 production: correlations with the course of disease.PLoS One. 2014 Jan 6;9(1):e84496. doi: 10.1371/journal.pone.0084496. eCollection 2014. PLoS One. 2014. PMID: 24400095 Free PMC article.
-
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Int J Mol Sci. 2016 Jun 27;17(7):1009. doi: 10.3390/ijms17071009. Int J Mol Sci. 2016. PMID: 27355944 Free PMC article. Review.
-
Adipogenic Mesenchymal Stromal Cells from Bone Marrow and Their Hematopoietic Supportive Role: Towards Understanding the Permissive Marrow Microenvironment in Acute Myeloid Leukemia.Stem Cell Rev Rep. 2016 Apr;12(2):235-44. doi: 10.1007/s12015-015-9639-z. Stem Cell Rev Rep. 2016. PMID: 26649729
-
A comprehensive analysis of cell-autonomous and non-cell-autonomous regulation of myeloid leukemic cells: The prospect of developing novel niche-targeting therapies.Cell Biol Int. 2023 Oct;47(10):1667-1683. doi: 10.1002/cbin.12078. Epub 2023 Aug 9. Cell Biol Int. 2023. PMID: 37554060 Review.
Cited by
-
Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives.Front Immunol. 2024 Aug 5;15:1403458. doi: 10.3389/fimmu.2024.1403458. eCollection 2024. Front Immunol. 2024. PMID: 39161767 Free PMC article. Review.
-
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway.Exp Hematol Oncol. 2025 Mar 22;14(1):43. doi: 10.1186/s40164-025-00635-6. Exp Hematol Oncol. 2025. PMID: 40121502 Free PMC article.
-
Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword.Cancer Cell Int. 2025 Mar 26;25(1):117. doi: 10.1186/s12935-025-03741-x. Cancer Cell Int. 2025. PMID: 40140850 Free PMC article. Review.
References
-
- Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., Deans R.J., Krause D.S., Keating A. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393–395. doi: 10.1080/14653240500319234. - DOI - PubMed
-
- Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317. doi: 10.1080/14653240600855905. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical